InvestSMART

Truscreen Group Limited (ASX:TRU)

ALERT: Price-sensitive ASX Announcement for TRU
Current share price for TRU : $0.013 -0.001 (-7.14%)+
Announcement
Release
25 Jun 2026 11:48AM
Price at Release
$0.014
Full Release
download
Summary
TruScreen Group Limited announced the successful completion of a substantially oversubscribed Rights Issue, part of a NZ$2.9 million capital raise. The company received applications for 171,653,080 shares, exceeding the offer by 15%. The funds raised, which bring the total capital raise to over NZ$4 million, will be used to take advantage of future opportunities. TruScreen is a medical device company known for its AI-enabled cervical cancer screening technology, TruScreen Ultra®, which allows for real-time detection of cervical tissue abnormalities without the need for biological sample processing.
Key Points
  • TruScreen Group Limited successfully completed a NZ$2.9 million capital raise.
  • The Rights Issue was oversubscribed with applications for 171,653,080 shares, exceeding the offer by 15%.
  • TruScreen plans to allot Rights Issue entitlements and Shortfall shares on 30 June 2026.
  • The company aims to raise just over NZ$4 million from the Placement and Rights Issue combined.
  • Funds will be used to capitalize on future opportunities.
  • TruScreen is a medical device company specializing in AI-enabled cervical cancer screening technology.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.